Targeting and blocking the SPP1/CD44 pathway has been shown to restore T cell function and inhibit tumor growth, suggesting that this pathway may serve as a promising therapeutic target for HCC (He et al., 2023). The gene discussed is CD44; the disease is hepatocellular carcinoma.